Genentech leaves the numbers blank in Forma deal

Genentech says that it's lined up the worldwide rights to a preclinical cancer program held by Forma Therapeutics in an "innovative" pact, but it's leaving all the numbers blank in its release. Following a research collaboration Genentech can pick up an option on the program, while Forma gets an undisclosed upfront payment along with more undisclosed dollars covering research funding. The biotech also is eligible to receive milestone payments upon the successful achievement of certain development milestones. And if Genentech subsequently acquires the program, Forma "will receive a significant buy-out payment and will be eligible for additional milestone payments if certain sales thresholds are met." Release